Acme United Corporation Reports First Quarter 2026 Financial Results

Key Highlights

• Net Sales Surge: Net sales for Q1 2026 increased to \$52.3 million, up 14% from \$46.0 million in Q1 2025. Excluding the impact of the My Medic acquisition, comparable sales rose by 6%.
• Acquisition Impact: The acquisition of My Medic (January 2026) contributed to sales growth but had minimal impact on Q1 earnings. My Medic, a direct-to-consumer tactical, trauma, and emergency response products business, is expected to generate most of its profits in Q4 due to seasonality.
• Net Income Declines: Net income fell to \$1.0 million (\$0.24 per diluted share) from \$1.7 million (\$0.41 per diluted share), a decrease of 40% and 41% respectively. This was primarily due to higher cost of sales, increased operating expenses, higher tariff-related costs, investments in quality assurance at the Med-Nap facility, and rising employee healthcare expenses.
• Tariff Impact: Elevated tariff expenses were recognized as the company sold inventory subject to higher 2025 tariff rates, affecting margins.
• Gross Margin Improvement: Gross margin improved slightly to 39.7% from 39.0%.
• Segment Performance:
  • U.S. Segment: Net sales increased 12%, driven by higher first aid and medical product sales and My Medic acquisition.
  • Europe: Net sales jumped 32% in USD (19% in local currency), with growth attributed to e-commerce and the acquisition of a German cutting and sharpening product line.
  • Canada: Net sales grew 16% in USD (11% in local currency), mainly from increased first aid product sales.
• Strategic Initiatives:
  • Acme United moved into a new Spill Magic facility in Tennessee, lowering expenses and providing expansion room.
  • Consolidated a Canadian site and is installing automation across facilities.
  • Expanding My Medic’s retail distribution and leveraging Acme United’s purchasing network for cost reduction.
  • One-time, non-recurring expenses for enhanced quality assurance protocols at Med-Nap.
• Inventory Management: Proactive inventory purchases (~\$10 million incremental orders) to mitigate potential shortages and price increases from the ongoing conflict in Iran. Additional purchases are being considered.
• Capital Expenditure and Acquisitions:
  • Paid ~\$14.6 million for My Medic acquisition (\$18.7 million purchase price less \$4.1 million holdbacks).
  • Acquired German cutting and sharpening line for ~\$1.6 million.
  • Purchased a Tennessee manufacturing/distribution facility for \$6.0 million (Spill Magic expansion).
  • Distributed ~\$2.4 million in dividends and generated ~\$14.2 million in free cash flow (before facility purchase).
• Balance Sheet:
  • Bank debt less cash as of March 31, 2026: \$38.6 million (up from \$27.2 million in 2025).
  • Total assets: \$195.2 million (up from \$163.0 million).
  • Total liabilities: \$78.5 million (up from \$54.8 million).
  • Stockholders’ equity: \$116.7 million (up from \$108.3 million).
• Conference Call: Acme United’s management will discuss quarterly results on April 23, 2026, at 12:00 p.m. ET. Investors can join via phone or webcast.

Risks and Matters of Shareholder Interest

• Profitability Concerns: Despite robust sales growth, profitability was impacted by rising costs, tariffs, and one-off expenses. This could affect near-term share price until efficiency and margin improvements materialize.
• Acquisition Integration: My Medic’s contribution to sales is positive, but its profitability is seasonal and expected mostly in Q4. Investors should monitor integration progress and cost synergies.
• Supply Chain Risks: Inventory build-up in anticipation of Iran conflict-related disruptions could affect cash flow and margins if demand does not materialize as expected.
• Debt and Cash Flow: Debt levels have increased due to acquisitions and facility purchases. While free cash flow remains strong, higher interest expenses and leverage warrant attention.
• One-Time Expenses: Some increased costs (Med-Nap quality protocols) were non-recurring. Excluding these, future quarters may see margin improvement.
• Tariff and Geopolitical Exposure: Exposure to tariffs and global conflict (Iran, Ukraine) could continue to affect costs and supply chain, with potential impact on pricing and margins.
• Growth Strategy: Expansion in Europe, Canada, and through new business lines (My Medic, Spill Magic) is positive, but execution risks remain.

Condensed Financials

Forward Looking Statements

The company has cautioned that forward-looking statements are subject to risks including changes in business strategies, volatility in global economic conditions, new tariffs and trade policies, inflation, conflicts in Ukraine and the Middle East, supply chain disruptions, labor costs, currency fluctuations, inventory management challenges, changes in consumer spending, competition, technological changes, and execution of growth and acquisition strategies.

Conclusion

Investor Takeaway: Acme United’s Q1 2026 report contains several price-sensitive elements:

• Strong top-line growth, driven by acquisitions and segment expansion.
• Significant margin and profit pressure from costs, tariffs, and non-recurring expenses.
• Seasonal nature of new businesses (My Medic) may delay profitability realization.
• Proactive inventory measures in response to geopolitical risks.
• Increased leverage and capital expenditure for growth initiatives.

Investors should monitor cost management, integration of acquisitions, supply chain resilience, and margin recovery in coming quarters. While long-term prospects appear favorable due to strategic expansion and automation, near-term volatility in earnings and increased debt could impact share price.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Financial figures are as reported by Acme United Corporation and may be subject to change. Investors should conduct their own due diligence and consult with a financial advisor before making investment decisions.

View ACME UNITED CORP Historical chart here